Format

Send to

Choose Destination
Biomed Pharmacother. 2018 Jan;97:1632-1638. doi: 10.1016/j.biopha.2017.11.076. Epub 2017 Dec 6.

NY-SAR-35 is involved in apoptosis, cell migration, invasion and epithelial to mesenchymal transition in glioma.

Author information

1
The Department of Neurosurgery, The Third Xiangya Hospital of Central South University, 138 Tongzipo Road, Yuelu District, Changsha, Hunan, China.
2
The Department of Neurology, The Second Xiangya Hospital of Central South University, China.
3
The Department of Neurosurgery, The Third Xiangya Hospital of Central South University, 138 Tongzipo Road, Yuelu District, Changsha, Hunan, China. Electronic address: drliangyang@yahoo.com.

Abstract

Glioma is one of the most adult intracranial tumors worldwide. Cancer testis antigens have been confirmed as new tool for immunotherapy and prognostic biomarkers in a variety of neoplasms. NY-SAR-35 has emerged to be upregulated in diverse human carcinomas. In this study, we aimed to investigate the role of NY-SAR-35 of clinical significance in glioma and investigate whether NY-SAR-35 correlate with malignant behaviors of glioma cells, including cell proliferation, apoptosis, migration, invasion and epithelial-to-mesenchymal transition (EMT). As the results showed, NY-SAR-35 was significantly upregulated in glioma clinical samples and cell lines, and the high expression was significantly associate with age (p = 0.05), the WHO classification (p = 0.02) and KPS score (p = 0.016). Therefore, NY-SAR-35 could serve as an independent prognostic biomarker of glioma patients. Moreover, increased NY-SAR-35 expression remarkably accelerated tumor cells proliferation, restrained cells apoptosis, promoted cells metastasis and contributed to the formation of EMT phenotype. Likewise, down-regulated NY-SAR-35 could obviously inhibit cells proliferation, promote cells apoptosis, supressed metastasis and reverse EMT to MET. In summary, our findings showed that NY-SAR-35 serves as a novel prognostic biomarker and therapeutic target for glioma.

KEYWORDS:

Cancer/testis antigen; Glioma; NY-SAR-35

PMID:
29793325
DOI:
10.1016/j.biopha.2017.11.076
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center